# Patent

## Title
Aminotetralin derivatives

## Abstract

The compounds of the present invention are useful as hypertensive agents.

## Background
This invention relates to new 1,5-benzothiazepine derivatives, therapeutic compositions containing these derivatives and the method of manufacturing the same.

The principal object of the present invention is the provision of novel compounds having advantageous pharmaceutical properties.

Another object of the present invention is the provision of pharmaceutical compositions useful as antihypertensive agents.

Still another object of the present invention is the provision of new 1,5-benzothiazepine derivatives and a method for the manufacture thereof.

These and other objects of the invention will become apparent from the description that follows.

This invention relates to new 1,5-benzothiazepine derivatives and their acid-addition salts, and a method of their synthesis and use as potent anti-hypertensive agents.

The compounds of this invention are represented by the general formula (I): ##STR5## wherein: A is >C.dbd.O or >CH.sub.2, ##STR6## wherein R.sup.1 represents H, an alkyl or acyl group,; R.sup.2 is ##STR7## D represents ##STR8## wherein n' and n" each represents 1 or 2. R, R', R" each represents a lower alkyl, Ph represents phenyl group or a substituted phenyl group.

and their acid-addition salts.

The acyl group indicated at R.sup.1 is, for example, an acetyl, propionyl or benzoyl groups.

The hydroxy lower alkyl of the symbol R.sup.2 is 2-hydroxypropyl or 2-hydroxy-1,1-dimethylethyl.

In case R.sup.2 is ##STR9## they are, for example, dimethylaminopropyl, and diethylaminoethyl.

Among the heterocyclic compounds represented by symbol B are N-methylpiperazino, N-phenylpiperazino or 4-(P-chlorophenyl)-4-hydroxypiperidino groups.

The compounds related to the general formula (I) are as follows. comp. ##STR10## No.   A       (CH.sub.2).sub.n B ______________________________________ 1 ##STR11## CH.sub.2 ##STR12## 2 ##STR13## CH.sub.2 ##STR14## 3 ##STR15## CH.sub.2 ##STR16## 4 ##STR17## CH.sub.2 ##STR18## 5 ##STR19## CH.sub.2 ##STR20## 6 ##STR21## CH.sub.2 ##STR22## 7 ##STR23## CH.sub.2 ##STR24## 8 ##STR25## CH.sub.2 ##STR26## 9 ##STR27## CH.sub.2 ##STR28## 10 ##STR29## CH.sub.2 ##STR30## 11 ##STR31## CH.sub.2 ##STR32## 12 ##STR33## CH.sub.2 ##STR34## 13 ##STR35## CH.sub.2 CH.sub.2 ##STR36## 14 ##STR37## CH.sub.2 CH.sub.2 ##STR38## 15 ##STR39## CH.sub.2 CH.sub.2 ##STR40## 16 ##STR41## CH.sub.2 CH.sub.2 ##STR42## 17    CH.sub.2 CH.sub.2 ##STR43## 18    CH.sub.2 CH.sub.2 ##STR44## 19 ##STR45## CH.sub.2 ##STR46## 20 ##STR47## CH.sub.2 ##STR48## 21 ##STR49## CH.sub.2 ##STR50## ______________________________________

The compounds of the general formula (I) can be prepared by the procedure of the present invention, and the first step is to react 2,3,4,5-tetrahydro-1,5 benzothiazepine the formula (II) with a compound of the formula (III) to give a compound of the general formula (IV). ##STR51##

The second step comprises reacting a compound of the general formula (IV) with a compound of the formula (V)

wherein Z is ##STR52## and other symbols are same as defined before, to give a compound of the general formula (VI). ##STR53##

The compound of the formula (II), 2,3,4,5-tetrahydro-1,5-benzothiazepine can be prepared according to the procedures of dibenzothiazepine described by H. L. Yale et al (Jour. Heterocycle. chem. 1972, 9, 899), replacing .alpha.,.gamma.-dibromopropane to O-aminothiophenol.

Alternatively, it can be obtained by reacting benzothiazole with 1,3-dibromopropane according to the method of H. J. Federsel (Tetrahedron. Lett. 21, 2429P. 1980). The compounds represented by the general gormula (III) are, for example, chloroacetyl chloride, bromoacetyl-bromide, 2-chloropropionyl chloride, and 3-chlorobutyryl chloride. The reaction of compounds (II) and (III) can be carried out in an inert solvent like benzene or toluene, but preferentially is carried out in a basic solvent such as triethylamine or pyridine. The reaction of compounds (IV) and (V) requires a base or a biequivalent amount of compound (V). As to the base required in this reaction, a compound such as triethylamine, pyridine, potassium carbonate, sodium ethylate, sodium amide and sodium hydride may be employed.

In the case of Z being --NH--ROH in the general formula (V), 2-hydroxypropylamine, 2-hydroxy-1,1-dimethylethylamine and diisopropylamine can be mentioned as examples. When Z is ##STR54## dimethylaminopropylamine and diethylaminoethylamine may be exemplified. When Z is --NH--(CH.sub.2)n"--NH--CH.sub.2 CH.sub.2 --Ph, 4-methoxyphenethylamine and 3,4-dimethoxyphenethylamine may be exemplified. Moreover, when Z is a heterocyclic compound, N-methylpiperazine, N-phenylpiperazine, 4-phenyl-4-hydroxypiperidine and 4-P-chlorophenyl-4-hydroxypiperidine may be examples in point. The compounds of the general formula (VII) are obtained by reducing a compound ##STR55## of the general formula (VI), using a reducing agent such as lithium aluminum hydride or sodium boron hydride. Ordinary acylation can be applied to react a compound of the general formula (VI) in the case of Z being ##STR56## with a compound of the general formula (VIII)

to give a compound of the general formula (IX). ##STR57##

The compounds of the general formula (I) and their pharmacologically acceptable acid-addition salts are therapeutically active compounds. Thus the compounds of the invention can be administered both perorally and parenterally in the form of tablets, capsules, granules, suppositories and injections. Doses to be administered to particular patients are various, depending on the patient's condition, patient's response or age. One effective dosage unit of the compound according to the present invention is from 100 mg to 250 mg for an adult, three times a day. The following example illustrates pharmacological data, a few pharmaceutical dosage unit compositions method of preparation thereof and procedures for preparing the active compounds.

Guinea-pig taenia cecum is isolated and suspended in a bath for 30 minutes. The normal-Ringer solution is then replaced by K.sup.+ --Ringer. In this condition, taenia cecum is contracted by elevating Ca.sup.++ --ion concentration of K.sup.+ --Ringer. Pretreatment by the compound of this invention inhibits this contraction. The potency of this inhibition is expressed as PA.sub.2 value (Table 2). Experiments are carried out according to M. Ferrari (Arch. Intern. Pharmacodyn. 174, 223-318 (1968)). ______________________________________ Compound No.    PA.sub.2 value ______________________________________ No.  1          6.77 No. 14          6.23 No. 16          6.72 No. 19          6.72 ______________________________________

The coronary artery dilating activity of the compounds is estimated by Rangendorf method (Pflugers. Arch. Ges. Physiol. 61, 291 (1895)) using the isolated guinea-pig heart. The maximum increased coronary blood flow and its increase % to control values are summarized in Table 3. ______________________________________ Compound concentration maximum increased increase No.     (.mu.g/heart) blood flow    (%) ______________________________________ 1      30           25.1 .+-. 3.5 53.1 .+-. 16.1 14      30           10.4 .+-. 6.8 20.2 .+-. 4.0 16      100          33.1 .+-. 8.1 37.6 .+-. 7.2 19      30           11.8 .+-. 3.5 40.7 .+-. 13.2 ______________________________________

The effects of the compounds of this invention on blood pressure of anesthetized normotensive rats are studied by intravenous injection of the compound.

The blood pressure of rats is monitored via a cannula inserted into the femoral artery by a transducer.

The results thus obtained are summarized in Table 4. ______________________________________ Compound      Dose     Decrease in blood No.           (mg/kg)  Pressure (mm Hg) ______________________________________ 1            1        36.6 .+-. 7.4 14            1        39.0 .+-. 11.6 19            1        29.4 .+-. 5.9 ______________________________________

The mode of vasorelaxing action of the compound of this invention is further studied accrding to method of S. Shibata et al. (European Journal of Pharmacology, 99 (1984) 219-226) using guinea pig aorta. In FIG. 1, the residual contractions induced by norepinephrine (10.sup.-4 M) in Ca.sup.++ --free medium in the presence of various drugs are shown. The known Ca.sup.++ --antagonists such as nifedipine, rerapamil and diltiazem can not suppress this contraction, but compound 14 suppresses it, dose-dependently.

The acute toxicity of the compounds of this invention in mice per os is as follows. ##TBL5##

The following examples illustrate the synthetic procedure to give the compound of this invention. It should be understood, however, that this invention is not limited solely to the particular examples given below.

To a solution of 7.63 g of 2,3,4,5-tetrahydro-1,5-benzothiazepine in 90 ml of toluene and 4.34 g of pyridine, is added a solution of 11.2 g of bromoacetylbromide in 40 ml of toluene dropwise during cooling in ice water with stirring. Then it is stirred continuously for 30 min. at temperature of 3.degree.-5.degree. C., then stirred at room temperature for 2 hours. The reaction mixture is filtered and the residue is washed with a small amount of toluene. Filtered and washed toluene is washed with a saturated sodium chloride solution and dried over anhydrous sodium sulfonate and then toluene is removed under reduced pressure. The residue (12.2 g) is recrystallized in ethanol to give the objective substance (10.98 g).

m.p.: 114.degree.-116.degree. C.

M.S. (m/e): 286 (M.sup.+).

I.R. (KBr): 2920, 2900, 1655, 1570 cm.sup.1.

To a solution of 0.5 g of N-bromoacetyl-2,3,4,5-tetrahydrobenzothiazepine in 1.5 ml of dichloromethane is added 0.29 g of 1-amino-2-propanol and the resulting solution is refluxed for 8 hours. After complete reaction, 10 ml of dichloromethane is added to the reaction mixture and the mixture is washed with a saturated sodium chloride solution and dried over anhydrous sodium sulfonate. The resultant crystals after removal of dichloromethane are washed with petroleum ether, thus yielding 0.33 g of the objective compound.

m.p.: 105.degree.-108.degree. C.

M.S. (m/e): 280 (M.sup.+).

I.R. (KBr): 3360, 2950, 2980, 1640, 1465 cm.sup.1.

The compounds from No. 2 to No. 16 are obtained by reacting a compound shown in column A of Table 6 which was obtained according to process 1 of Example 1 with a compound in column B of Table 6 in the process 2 of Example 1. ##TBL6## benzothiazepine (compound 17)

1.2 g of compound of example 9, 5-[2-[4-(p-chlorophenyl)-4-hydroxypiperidino-]-1-acetyl]-2,3,4,5-tetrahydr o-1,5-benzothiazepine is dissolved in 30 ml of anhydrous ether, then 0.327 g of lithium aluminum hydride is added to this solution. After 30 hours' reflux to the reaction mixture is added a small amount of saturated ammonium chloride under cooled conditions with in an ice-water bath, then Celite is added. To remove this Celite, the mixture is filtered. The aqueous layer is extracted with ether. The ether layer thus obtained is washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfonate and concentrated under reduced pressure. The residue is recrystallized with ether, giving 0.24 g of the objective substance.

m.p.: 95.degree.-98.degree. C.

M.S. (m/e): 402 (M.sup.+).

I.R. (KBr): 3700, 3360, 2920, 2800, 1570, 1470 cm.sup.1.

Reducing compounds 1 and 11 which were obtained by Example 1 and Example 11 by the same procedure of Example 17 will give the compounds 18 and 19. pine benzothiazepine (Compound 20)

To a solution of 0.5 g. of N-[2-(N'-.beta.-phenethylamino)-1-acetyl]-2,3,4,5-tetrahydro-1,5-benzothia zepine in 7 ml of benzene, is added 0.2 g of acetylchloride is dropwise and then is added 0.17 g of triethylamine under cooled conditions in an ice-water bath. Then the mixture solution is reacted at room temperature by stirring overnight. The reaction mixture is then poured in ice-water and extracted with benzene. The benzene layer is washed with a saturated sodium sulfonate solution and dried. The residue after removal of benzene is recrystallized from benzene to give 0.25 g of the objective substance.

m.p.: 163.degree.-166.degree. C.

M.S. (m/e): 369 (M.sup.+ +1).

I.R. (KBr): 3450, 1660, 1640, 1470 cm.sup.-1. ,5-benzothiazepine (Compound 21)

The same procedure of example 20 is applied, using propionyl chloride instead of acetyl chloride to give the objective substance.

m.p.: 156.degree.-158.degree. C.

M.S. (m/e): 384 (M.sup.+ +1).

The following examples illustrate a few pharmaceutical dosage unit compositions comprising the compound of the present invention as an active ingredient. The parts given below are by weight.

The ingredients are intimately admixed with each other, and the resulting mixture is compressed into 150 mg-tablets in a conventional manner.

Capsule fillers having the same compositions as example 22 are filled into gelatin capsules of a suitable size in a conventional manner.

The admixed ingredients of compound 16, lactose and cornstarch are granulated using a methyl cellulose solution and dried to make granules.

The ingredients are suspended in 100 parts of water in a conventional manner.

## Claims

1. A compound of the formula: ##STR58## wherein: A is >C.dbd.O or >CH.sub.2 ; group, the group ##STR59## wherein R' and R" each represent a lower alkyl group and n" is 1 or 2, or the group or chloro groups

2. The compound according to claim 1, wherein R.sup.1 is hydrogen.

3. The compound according to claim 1 wherein B is R.sup.2 is --CH.sub.2 CH.sub.2 --Ph.

4. The compound according to claim 1, wherein R.sup.1 is hydrogen and R.sup.2 is --CH.sub.2 CH.sub.2 --Ph.

5. The compound according to claim 1, wherein R.sup.1 is hydrogen and R.sup.2 is --CH.sub.2 CH.sub.2 --Ph, wherein Ph is a phenyl or methoxy-substituted phenyl group.

6. The compound according to claim 1, wherein A is >C.dbd.O and n is 1 or 2.

7. The compound according to claim 1, wherein A is >C.dbd.O, B is R.sup.1 is hydrogen and R.sup.2 is --CH.sub.2 CH.sub.2 Ph.

8. The compound according to claim 1, wherein n is 1 or 2, R.sup.1 is hydrogen and R.sup.2 is --CH.sub.2 CH.sub.2 Ph.

9. The compound according to claim 1 which is 5-[3-(3,4-dimethoxy-.beta.-phenylethylamino)-1-propionyl]-2,3,4,5-tetrahyd ro-1,5-benzothiazepine.

10. The compound according to claim 1 which is 5-[3-(.beta.-phenethylamino)-1-propionyl]-2,3,4,5-tetrahydro-1,5-benzothia zepine.

11. The compound according to claim 1 which is 5-[2-(3,4-dimethoxy-.beta.-phenylethylamino)-1-ethyl]-2,3,4,5-tetrahydro-1 ,5-benzothiazepine.

12. The compound according to claim 1 which is 5-[2-(2-hydroxypropylamino]-1-acetyl]-2,3,4,5-tetrahydro-1,5-benzothiazepi ne.

13. The compound according to claim 1 in which R.sup.2 is ##STR60##

14. The compound according to claim 1 wherein R.sup.2 is --CH.sub.2 CH.sub.2 --Ph.

15. The compound according to claim 1 wherein Ph is a phenyl or lower alkoxyphenyl group.

16. The compound according to claim 1 wherein Ph is a phenyl or methoxyphenyl group.

17. A therapeutic composition to inhibit hypertension comprising a pharmaceutically acceptable carrier and as an active ingredient a compound defined in claim 1 in an amount effective to inhibit hypertension.